Voor zorgverleners

Glycaemic Targets and Vascular Complications in Type 2 Diabetes: What Are the Thresholds?

Summary of Zoungas S, et al. Diabetologia. 2012;55:636–643.

Cardiovascular diseases (CVDs) are the leading cause of death globally

Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

Approach for patients with coronary artery disease (CAD): focus on LDL-C control

Why choose PRALUENT®?

The usual starting dose for PRALUENT is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.²

PRALUENT is available as a unique,¥ once-monthly pen

What is PRALUENT®?

PRALUENT^®: a powerful PCSK9i that ticks all the boxes^1–4

How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

Summary of The UK Prospective Diabetes Study (UKPDS).

Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?

Summary of Aschner P, et al. Diabetologia. 2020;63(4):711-721.